Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Benzo(a)pyrene | 11 | 2020 | 128 | 1.720 |
Why?
|
| Hydroxyurea | 3 | 2023 | 34 | 1.160 |
Why?
|
| Hypogonadism | 2 | 2023 | 23 | 1.100 |
Why?
|
| Testis | 7 | 2023 | 207 | 1.090 |
Why?
|
| Endocrine Disruptors | 5 | 2023 | 44 | 0.870 |
Why?
|
| Carcinogens | 3 | 2012 | 126 | 0.610 |
Why?
|
| Ovary | 4 | 2013 | 113 | 0.600 |
Why?
|
| Fertility | 3 | 2023 | 62 | 0.570 |
Why?
|
| Infertility, Male | 2 | 2014 | 47 | 0.400 |
Why?
|
| Fetus | 1 | 2012 | 101 | 0.370 |
Why?
|
| Rats, Inbred F344 | 8 | 2012 | 258 | 0.360 |
Why?
|
| Premenstrual Syndrome | 2 | 2023 | 13 | 0.320 |
Why?
|
| Sperm Motility | 3 | 2023 | 47 | 0.320 |
Why?
|
| Antisickling Agents | 1 | 2009 | 14 | 0.300 |
Why?
|
| Environmental Pollutants | 5 | 2014 | 201 | 0.290 |
Why?
|
| Luteinizing Hormone | 4 | 2012 | 61 | 0.290 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 247 | 0.280 |
Why?
|
| Animals | 19 | 2023 | 16992 | 0.270 |
Why?
|
| Spermatozoa | 2 | 2014 | 214 | 0.270 |
Why?
|
| Testosterone | 6 | 2023 | 211 | 0.260 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2011 | 27 | 0.260 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 187 | 0.250 |
Why?
|
| Liver | 5 | 2020 | 511 | 0.240 |
Why?
|
| Rats | 10 | 2012 | 3735 | 0.240 |
Why?
|
| Epididymis | 1 | 2003 | 29 | 0.200 |
Why?
|
| Semen | 1 | 2023 | 57 | 0.190 |
Why?
|
| Fetal Death | 1 | 2002 | 18 | 0.190 |
Why?
|
| Administration, Inhalation | 3 | 2012 | 92 | 0.190 |
Why?
|
| Female | 19 | 2023 | 24698 | 0.190 |
Why?
|
| Mice | 9 | 2023 | 6644 | 0.190 |
Why?
|
| Spermatogenesis | 1 | 2023 | 161 | 0.180 |
Why?
|
| Male | 13 | 2023 | 23409 | 0.180 |
Why?
|
| Estrogens | 3 | 2023 | 203 | 0.170 |
Why?
|
| Atmospheric Pressure | 1 | 2020 | 11 | 0.160 |
Why?
|
| Pressure | 1 | 2020 | 50 | 0.160 |
Why?
|
| Metformin | 2 | 2011 | 75 | 0.160 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 182 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 280 | 0.150 |
Why?
|
| Progestins | 1 | 2018 | 11 | 0.140 |
Why?
|
| Litter Size | 2 | 2012 | 14 | 0.140 |
Why?
|
| Contraceptives, Oral | 1 | 2018 | 17 | 0.140 |
Why?
|
| Endometriosis | 1 | 2020 | 83 | 0.140 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 44 | 0.140 |
Why?
|
| Progesterone | 2 | 2012 | 121 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 223 | 0.140 |
Why?
|
| Contraception | 1 | 2018 | 60 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2018 | 187 | 0.130 |
Why?
|
| Microsomes, Liver | 2 | 2007 | 75 | 0.120 |
Why?
|
| Arrestins | 1 | 2015 | 28 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 1596 | 0.120 |
Why?
|
| Ovulation | 2 | 2012 | 21 | 0.120 |
Why?
|
| Estrous Cycle | 2 | 2012 | 37 | 0.110 |
Why?
|
| Caloric Restriction | 2 | 2011 | 34 | 0.100 |
Why?
|
| Receptors, FSH | 2 | 2012 | 8 | 0.100 |
Why?
|
| Microsomes | 3 | 2009 | 55 | 0.100 |
Why?
|
| Prolactin | 2 | 2023 | 65 | 0.100 |
Why?
|
| Biological Availability | 4 | 2010 | 116 | 0.100 |
Why?
|
| Premature Birth | 1 | 2014 | 95 | 0.100 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2012 | 43 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1124 | 0.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 192 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 51 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 19 | 0.090 |
Why?
|
| Ovarian Follicle | 1 | 2012 | 44 | 0.090 |
Why?
|
| Estradiol | 1 | 2012 | 268 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 138 | 0.080 |
Why?
|
| DNA Adducts | 1 | 2010 | 37 | 0.080 |
Why?
|
| Blastocyst | 1 | 2010 | 50 | 0.080 |
Why?
|
| Lung | 1 | 2012 | 492 | 0.080 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 44 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 758 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 184 | 0.070 |
Why?
|
| Radioimmunoassay | 2 | 2010 | 70 | 0.070 |
Why?
|
| Phenotype | 1 | 2011 | 780 | 0.070 |
Why?
|
| Depression | 1 | 2015 | 863 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 147 | 0.070 |
Why?
|
| Organ Size | 1 | 2008 | 170 | 0.070 |
Why?
|
| Pregnancy | 3 | 2014 | 1772 | 0.070 |
Why?
|
| Time Factors | 2 | 2011 | 1857 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 665 | 0.060 |
Why?
|
| Humans | 11 | 2023 | 43102 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2005 | 25 | 0.060 |
Why?
|
| Fluorenes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Exercise | 1 | 2010 | 692 | 0.050 |
Why?
|
| Fluorescence | 2 | 2020 | 118 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2023 | 17 | 0.050 |
Why?
|
| Sheep | 3 | 2009 | 77 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 458 | 0.050 |
Why?
|
| Reproduction | 1 | 2023 | 94 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2012 | 1604 | 0.050 |
Why?
|
| Embryo Implantation | 1 | 2002 | 31 | 0.050 |
Why?
|
| Swine | 3 | 2009 | 212 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 760 | 0.050 |
Why?
|
| Maternal Exposure | 1 | 2002 | 57 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2002 | 83 | 0.050 |
Why?
|
| Cattle | 3 | 2009 | 498 | 0.040 |
Why?
|
| Carcinogens, Environmental | 1 | 2001 | 35 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 1869 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2011 | 317 | 0.040 |
Why?
|
| Porosity | 1 | 2020 | 43 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 5080 | 0.040 |
Why?
|
| Adolescent | 3 | 2018 | 6081 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2020 | 169 | 0.040 |
Why?
|
| Solvents | 1 | 2020 | 113 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 13872 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 638 | 0.040 |
Why?
|
| Tennessee | 1 | 2018 | 93 | 0.040 |
Why?
|
| Water | 1 | 2020 | 316 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2012 | 1035 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 3994 | 0.030 |
Why?
|
| Quality of Life | 2 | 2011 | 616 | 0.030 |
Why?
|
| Cricetinae | 2 | 2007 | 241 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2010 | 260 | 0.030 |
Why?
|
| Species Specificity | 2 | 2007 | 286 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2013 | 77 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 465 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 14 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2010 | 10 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2010 | 23 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 173 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2010 | 32 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2011 | 87 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2010 | 5 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 490 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 62 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 38 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 165 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 101 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 701 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 334 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 652 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 863 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1285 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2007 | 56 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 141 | 0.020 |
Why?
|
| Haplorhini | 1 | 2005 | 23 | 0.010 |
Why?
|
| Goats | 1 | 2005 | 23 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 204 | 0.010 |
Why?
|
| Genitalia, Male | 1 | 2001 | 14 | 0.010 |
Why?
|
| United States | 1 | 2011 | 5205 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 12222 | 0.000 |
Why?
|